focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPPIX.L Regulatory News (PPIX)

  • There is currently no data for PPIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ProPhotonix Announces Cobra Cure (TM)FX UV LED

9 Sep 2015 07:00

RNS Number : 4677Y
ProPhotonix Limited
09 September 2015
 

 

September 9, 2015

 

ProPhotonix Limited

("ProPhotonix" or "the Company")

ProPhotonix introduces COBRA Cure™ FX UV LED Lamp with IntelliSenseTM Smart Sensing Technology

Stackable Design, Field-Replaceable Window, Multiple Optical Output Options, Innovative sensing software

 

ProPhotonix Limited (London Stock Exchange - AIM: PPIX and, OTC: STKR), a high technology designer and manufacturer of LED illumination systems and laser diode modules, today announces the launch of the COBRA Cure FX, a UV LED lamp ideally suited to a range of ultra violet ("UV") curing applications. COBRA Cure FX is a patent pending, compact, fan-cooled UV LED lamp in a stackable form factor that produces a uniform line with a peak irradiance of 4 W/cm2 and peak energy density (dose) of 3 J/cm2. COBRA Cure FX is offered in numerous optical configurations and is available in a range of wavelengths including 365nm, 385nm 395nm and 405nm. Multiple wavelength versions are also available.

LED illumination offers significant benefits versus traditional UV lamps including longer illuminator lifetimes, high stability light output, precise control, thermal management, ozone-free, heavy metal free, and lower total cost of ownership.

 

The COBRA Cure FX unique design includes a field-replaceable exit window. In certain operating environments, materials can build-up over time on the outer surface of the window which reduces the intensity of the light causing a degradation of system performance. Without this unique design, the operator must manually clean the emitter window which causes machine down time but also causes abrasion damage to the window thus reducing the light's effectiveness during operation. The field-replaceable window allows fast and efficient changes by non-technical personnel. This innovative patent pending design is easy to use, requires no special tools for window replacement, and ensures that the window is secure during operation, thus minimizing system downtime.

COBRA Cure FX also incorporates IntelliSense, a patent pending new smart sensing technology which provides precise output control, operational intelligence and "Plug & Play" integration for end users. Sensing features include: real-time thermal monitoring, a necessity ensuring proper system operation; intensity monitoring, providing operating irradiance and efficiency data; lifetime prediction of the lamp, reliability and longevity estimates; and numerous health & safety features. IntelliSense is the state of the art sensing capability in illumination.

Commenting on the COBRA Cure FX launch, Tim Losik, CEO and President of ProPhotonix, said:

"Over the past two years we have assessed various markets and product features and have developed a product strategy focusing on large markets complemented by our design capabilities. To this end, we are concentrating our engineering talents in a couple of specific market areas which we believe are poised for fast market expansion. One of these is the ultra violet LED and laser market, addressing various applications including: printing, curing, 3D printing, bio-luminescence, medical microscopy, and other applications. Market research shows that the 2014 market size for UV LED applications was approximately $90 million with projected growth to $500 million by 2019, a compound average annual growth rate of nearly 40%.

"This product redefines the capabilities of the world's best UV LED lamps by increasing the operational capabilities and improving customer ease of use. As this product line develops, we intend to introduce more exciting enhancements and capabilities for users. To protect our intellectual property rights within this product, United States Patent Applications have recently been filed covering several of the unique features of the product design including the capabilities of IntelliSense. We will continue to file patent applications, where appropriate, to protect our expanding intellectual property portfolio."

 

For more information about ProPhotonix' COBRA Cure FX, visit http://www.prophotonix.com/products/UV-Solutions/

 

Enquiries:

ProPhotonix Limited

Tim Losik

 

sales@prophotonix.com

 

Tel: +1 603 893 8778

 

N+1 Singer

Ben Wright/ Richard Salmond

Tel: +44 (0) 207 496 3000

Nominated Adviser and Broker

 

About ProPhotonix

 

ProPhotonix Limited, headquartered in Salem, New Hampshire, is a high technology designer and manufacturer of LED illumination systems and laser diode modules for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Ushio (formerly Opnext), Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, ultra violet applications, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at www.prophotonix.com.

 

 

Cautionary Statement 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances may not be sufficient to allow ProPhotonix to meet all of its business goals; uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.

 

 

 

 

 

 

 

 

 

 

#######

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADVLFBEKFEBBD
Date   Source Headline
13th Aug 20127:00 amRNSHalf Yearly Report
25th May 20122:30 pmRNSGrant of Options (Replacement)
17th May 20127:00 amRNSAGM Statement
1st May 20124:21 pmRNSPosting of Annual Report and Accounts
5th Apr 20127:00 amRNSAppointment of Three New Distribution Partners
26th Mar 20127:00 amRNSGrant of Options
19th Mar 20127:00 amRNSAppointment of Joint Broker
1st Mar 20127:00 amRNSFinal Results
1st Feb 20127:00 amRNSChange of Name of Nominated Adviser and Broker
19th Jan 20127:00 amRNSTrading Update and New Product Launch
27th Oct 20117:00 amRNS3rd Quarter Results
28th Jul 20117:00 amRNSHalf Yearly Report
20th Jul 20117:00 amRNSNotice of Results
13th Jul 20117:00 amRNSIssue of Equity
26th May 20111:51 pmRNSDirector/PDMR Shareholding
24th May 20115:09 pmRNSDirector/PDMR Shareholding
10th May 20117:00 amRNSChange of Adviser
4th May 20117:00 amRNS1st Quarter Results
19th Apr 20115:28 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.